FA at 100 mg/m 2 as 2 h infusion on days 1-2, FU at 400 mg/m 2 as bolus on days 1-2 plus FU at 600 mg/m 2 as 22 h infusion on days 1-2 (folfiri) every 2 weeks, or arm B: Cpt-11 at 250 mg/m 2 on day 1 and xeloda 2000 mg/m 2 for 14 days (xeliri) every 3 weeks.
Results: Up to now 91 patients have been enrolled: 54 are evaluable for activity and toxicity (A/B: 20/34). The main characteristics of the evaluable patients are (A/B): median PS: 0/0; sites of disease: liver 12/26, lung 7/15, lymph-nodes 1/8, others 3/4. Among the evaluable patients we observed the following responses (A/ B) CR: 1/0 (5/0%), PR: 4/18 (20/53%), SD: 11/11 (55/32%) and PRO: 4/5 (20/15%) for an ORR of 25% and 53%, respectively. Grades 3-4 haematologic toxicity (NCI criteria) were: neutropenia 15/21% and anaemia 5/3% whilst the main non haematologic side effect was diarrhoea observed in 5/18%, respectively.
Conclusions:
Our preliminary results do not permit any definitive conclusion regard the activity of the two combinations.
The toxicity profile of xeliri is similar to those of previous studies. Background: The addition of bevacizumab (BEV) to irinotecan (CPT-11) plus bolus fluorouracil (FU) and folinic acid (FA) (IFL regimen) demonstrated to be more active and more effective than chemotherapy alone in a randomised phase III trial. However IFL is considered more toxic than FOLFIRI regimen. So we started a phase II trial to evaluate the activity and the safety of the combination of BEV plus FOLFIRI as first-line therapy in ACC patients (pts). The enrolled pts were treated with CPT-11 at 180 mg/m 2 on day 1, FA at 100 mg/m 2 as 2 h infusion on days 1-2, FU at 400 mg/m 2 as bolus on days 1-2 and FU at 600 mg/m 2 as 22 h infusion on days 1-2 (FOLFIRI) plus BEV at the dosage of 5 mg/kg on day 1, every two weeks. A maximum of 12 cycles of chemotherapy was planned and a maintenance with BEV for 6 months was permitted. The evaluation of the activity (recist criteria) was performed every four cycles.
Methods
Results: Up to now 72 pts have been enrolled and 61 are evaluable for activity and safety (eleven pts are too early). The main characteristics of the evaluable pts were M/F: 32/29; median PS: 0 (range 0-2); median age 61 (range 33-73); primary site (colon/ rectum): 40/21; main sites of disease: liver 45, lung 16, lymphnodes 15, others 6; single site: 39 and multiple sites: 22.
Three CR (5%) and 25 PR (41%) were observed for an ORR of 46%; 26 pts had SD (43%) for an overall TGCR of 89%. Only 7 PRO (11%) were observed. The response rate according to site were: liver 21/45 (46.6%), lung 8/16 (50%). The only grades 3-4 toxicity (NCI criteria) were neutropenia 10% and thrombocytopenia 2%. Ten pts (16%) had hypertension but only one was uncontrolled by medical therapy and interrupted the study. One pts had epistaxis.
Conclusions:
Our results indicate that the addition of BEV to FOLFIRI regimen is an active and well tolerated first-line treatment for ACC pts. Final data will be available for the meeting. Background: Radiochemotherapy of anal carcinoma is an organ sparing approach with a high curative potential. 
